Read by QxMD icon Read

Hepatitis b treatment adherence

Pietro Lampertico, Kosh Agarwal, Thomas Berg, Maria Buti, Harry L A Janssen, George Papatheodoridis, Fabien Zoulim, Frank Tacke
Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection. Chronic HBV infection can be classified into five phases: (I) HBeAg-positive chronic infection, (II) HBeAg-positive chronic hepatitis, (III) HBeAg-negative chronic infection, (IV) HBeAg-negative chronic hepatitis and (V) HBsAg-negative phase...
April 18, 2017: Journal of Hepatology
Young-Suk Lim, Yung Sang Lee, Geum-Youn Gwak, Kwan Soo Byun, Yoon Jun Kim, Jonggi Choi, Jihyun An, Han Chu Lee, Byung Chul Yoo, So Young Kwon
Combination therapy has been recommended for the treatment of patients harboring multiple drug-resistant hepatitis B virus (HBV). However, we recently demonstrated that monotherapy with tenofovir disoproxil fumarate (TDF) for 48 weeks displayed non-inferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with HBV resistant to multiple drugs, including ETV and adefovir, respectively. Nonetheless, whether prolonged TDF monotherapy would be safe and increase the virologic response rate in these patients was unclear...
March 30, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Weiyan Yu, Yadong Wang, Chuan Shen, Ru Ji, Li Zhang, Xin Zhao, Miao Su, Yin Zhang, Wenyan He, Jianguo Cao, Yanshuang Hao, Shengpeng Chen, Caiyan Zhao
AIMS: To evaluate the HBeAg seroconversion rate in real clinical setting and explore its predictors in long-term nucleos(t)ide analogues (NAs) treatment for chronic hepatitis B (CHB). METHODS: 251 patients were recruited from January 2001 to September 2009 in four hospitals in HeBei province, China, for this retrospective study. Clinical and laboratory data before and after treatment with lamivudine (LAM, 100mg daily), adefovir (ADV, 10mg daily), telbivudine (LDT, 600mg daily), ETV (0...
March 25, 2017: Brazilian Journal of Infectious Diseases
Carlos Rodríguez de Lope, María Reig, Ana Matilla, María Teresa Ferrer, Eva Dueñas, Beatriz Mínguez, Javier F Castroagudín, Inmaculada Ortiz, Sonia Pascual, José Luis Lledó, Adolfo Gallego, Juan I Arenas, Carles Aracil, Montserrat Forne, Carolina Muñoz, Fernando Pons, Margarita Sala, Mercedes Iñarrairaegui, Marta Martin-Llahi, Victoria Andreu, Carmen Garre, Paloma Rendón, Javier Fuentes, Javier Crespo, Manuel Rodríguez, Jordi Bruix, María Varela
BACKGROUND AND OBJECTIVE: In 2010 we published that 53% of cases of hepatocellular carcinoma (HCC) detected in Spain were diagnosed outside the context of standard screening programs, which consequently leads to lower survival rates. The aim of this study was to analyze the current situation and the causes of diagnosis out of screening programs. MATERIAL AND METHODS: Prospective registry of 73 second- and third-level Spanish healthcare centers carried out between October 1, 2014 and January 31, 2015...
March 6, 2017: Medicina Clínica
Jennifer B Lai, Maxwell A Witt, Mary Patricia Pauly, Joanna Ready, Michael Allerton, Suk Seo, David J Witt
BACKGROUND: Second-generation direct-acting antiviral agents are integral to treatment of hepatitis C (HCV) infection. Eight-week courses of ledipasvir/sofosbuvir (LDV/SOF) have been supported in some studies, but data are limited on efficacy in real-world use. Controversy exists regarding applicability of clinical trials to real-world effectiveness. We report virologic responses of patients with HCV genotype 1 infection receiving LDV/SOF for 8 or 12 weeks in a large integrated healthcare system...
March 2017: Drugs
Theodoros Voulgaris, John Vlachogiannakos, Panagiota Ioannidou, Maria-Vasiliki Papageorgiou, Evi Zampeli, Dimitrios Karagiannakis, Anastasia Georgiou, Afroditi Papazoglou, George Karamanolis, George V Papatheodoridis
BACKGROUND/AIM: Immigrants have multiple barriers to access to health care systems. We evaluated the adherence to follow-up and treatment recommendations of chronic hepatitis B virus (HBV) Greek and immigrant patients. METHODS: In total, 1001 consecutive adult patients with chronic HBV infection who visited our clinics for the first time between 2002 and 2011 were included. All patients born outside Greece were considered immigrants. Diagnosis was considered to be complete if patients could be classified into HBeAg-positive chronic hepatitis B (CHB), inactive carriers, HBeAg-negative CHB, or decompensated cirrhosis...
March 2017: European Journal of Gastroenterology & Hepatology
Nizar A Mukhtar, Priya Kathpalia, Joan F Hilton, Gene Lau, Albert Yu, Kevin Grumbach, Tung T Nguyen, Daniel Chan, Mandana Khalili
GOALS: To evaluate provider knowledge, attitudes and barriers to hepatitis B virus (HBV) care and management practices across diverse primary care settings. BACKGROUND: Factors influencing adherence to recommended HBV screening and management guidelines are poorly defined. MATERIALS AND METHODS: Providers across various health care settings in San Francisco were surveyed. Multivariate analyses were used to identify factors associated with recommended HBV screening, vaccination, and disease monitoring...
November 2, 2016: Journal of Clinical Gastroenterology
L P Zanaga, N Miotto, L C Mendes, R S B Stucchi, A G Vigani
Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatocellular carcinoma and lower sustained virological response (SVR) rates. Currently there are 4 recommended drugs for the treatment of HCV genotype 3: pegylated interferon (PegIFN), sofosbuvir (SOF), daclatasvir (DCV) and ribavirin (RBV)...
October 24, 2016: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
Frank Tacke, Daniela C Kroy
Persistent hepatitis B virus (HBV) infections affect about 240 million patients worldwide that are at risk of developing liver cirrhosis or hepatocellular carcinoma. HBV is a small, partially double stranded DNA virus with four overlapping genes and a unique life cycle, which involves the generation of an RNA template for replication via reverse transcription. Mutations occur frequently during chronic infection, and particular selection pressures select distinct mutants. Nucleoside and nucleotide analogues like lamivudine (LMV), entecavir (ETV), telbivudine (LdT), adefovir dipivoxil (ADV) and tenofovir (TDF) are used to achieve long-term suppression of viral replication...
September 2016: Annals of Translational Medicine
Hanan H Balkhy, Aiman El-Saed, Faisal M Sanai, Mohammad Alqahtani, Mashael Alonaizi, Nermeen Niazy, Abdulrahman Aljumah
BACKGROUND: Non-adherence with recommended follow-up visits is a major barrier for completing treatment of viral hepatitis and is consequently associated with unfavorable outcomes of health services. OBJECTIVES: To estimate the magnitude and identify perceived reasons and patient characteristics associated with loss to follow-up in a tertiary care setting. METHODS: A two-step cross-sectional study design was used, including a chart review (2011) followed by phone survey (2012)...
October 6, 2016: Journal of Infection and Public Health
Kali Zhou, Thomas Fitzpatrick, Nick Walsh, Ji Young Kim, Roger Chou, Mellanye Lackey, Julia Scott, Ying-Ru Lo, Joseph D Tucker
BACKGROUND: Advances in therapy for hepatitis B virus (HBV) and hepatitis C virus (HCV) have ushered in a new era in chronic hepatitis treatment. To maximise the effectiveness of these medicines, individuals must be engaged and retained in care. We analysed operational interventions to enhance chronic viral hepatitis testing, linkage to care, treatment uptake, adherence, and viral suppression or cure. METHODS: We did a systematic review of operational interventions, and did meta-analyses for sufficiently comparable data...
December 2016: Lancet Infectious Diseases
N Allard, A Dev, J Dwyer, G Srivatsa, A Thompson, B Cowie
Antiviral therapy for hepatitis B is effective and reduces the risk of progression to cirrhosis and liver cancer but is often required for an indefinite duration. Treatment adherence is important to prevent the development of resistance and optimize outcomes. Pharmacy adherence measures can be used to assess treatment adherence, with the medication possession ratio being less susceptible to bias than physician- or self-reported adherence. The aim of this study was to measure adherence in public hospital outpatients over a 3-year period and to examine factors associated with nonadherence...
January 2017: Journal of Viral Hepatitis
Alexandre Pierre Benechet, Matteo Iannacone
Antigen-specific effector CD8(+) T cells play a critical role in controlling hepatic infections, such as the one caused by hepatitis B virus (HBV). We review here recent results where we coupled advanced dynamic imaging with dedicated mouse models of HBV pathogenesis to show that circulating effector CD8(+) T cells aimed at viral clearance initially arrest in liver sinusoids by preferentially docking onto platelets that have previously adhered to liver sinusoids. Upon detachment from platelets, effector CD8(+) T cells crawl within the sinusoids irrespective of bloodstream direction, and probe underlying hepatocytes for the presence of antigen by extending filopodia-like protrusions through the sinusoidal fenestrae...
January 2017: Journal of Hepatology
Karoline Aebi-Popp, Christian Kahlert, Andri Rauch, Beatrice Mosimann, David Baud, Nicola Low, Daniel Surbek
QUESTION: Detection and treatment of infections during pregnancy are important for both maternal and child health. The objective of this study was to describe testing practices and adherence to current national guidelines in Switzerland. METHODS: We invited all registered practicing obstetricians and gynaecologists in Switzerland to complete an anonymous web-based questionnaire about strategies for testing for 14 infections during pregnancy. We conducted a descriptive analysis according to demographic characteristics...
2016: Swiss Medical Weekly
Lai Wei, Ji-Dong Jia, Xin-Hua Weng, Xiao-Guang Dou, Jia-Ji Jiang, Hong Tang, Qin Ning, Qing-Qing Dai, Run-Qin Li, Jie Liu
AIM: To investigate Chinese physicians' awareness of the 2010 guidelines on the treatment of chronic hepatitis B virus (HBV) infection. METHODS: This was a quantitative survey that investigated the characteristics and practices of physicians who were treating patients with hepatitis B, the profile of their patients and physician practices regarding the diagnosis and treatment of HBV at the time of the survey. Participants were randomly selected from available databases of Chinese physicians and requested to complete either an online or paper-based survey...
June 28, 2016: World Journal of Hepatology
Derek Ems, Patrick Racsa, Chris Anderson, Fran Gregory, Karen Worley, Joel V Brill, Worthe Holt
BACKGROUND: Chronic hepatitis C virus (HCV) is the primary cause of liver failure leading to transplantation, and medication adherence is essential to the therapeutic efficacy of HCV treatments. While there is evidence linking poor adherence with increased utilization and cost, published literature lacks examination of the association between medication adherence and risk of liver transplant. In addition, the impact of HCV treatment on total costs of liver transplantation is not well documented...
July 2016: Journal of Managed Care & Specialty Pharmacy
Timothy Na Archampong, Ceejay L Boyce, Margaret Lartey, Kwamena W Sagoe, Adjoa Obo-Akwa, Ernest Kenu, Jason T Blackard, Awewura Kwara
BACKGROUND: The presence of HBV resistance mutations upon initiation or during antiretroviral therapy (ART) in HIV-coinfected patients is an important determinant of treatment response. The main objective of the study was to determine the prevalence of HBV resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected Ghanaian patients with detectable HBV viraemia. METHODS: HBV-HIV-coinfected patients who were ART-naive or had received at least 9 months of lamivudine (3TC)-containing ART were enrolled in a cross-sectional study...
2017: Antiviral Therapy
Adeline M Nyamathi, Sheldon X Zhang, Sarah Wall, Elizabeth A Hall, Benissa E Salem, David Farabee, Mark Faucette, Kartik Yadav
BACKGROUND: Transitioning into society after release from incarceration presents real challenges for male offenders; in California, up to 60% return to prison within 3 years after release. The risk for ongoing drug use and having sex with multiple partners is a significant challenge for ex-offenders preparing to enter the community. OBJECTIVES: The aims are to describe drug use and sexual behavior (sex with multiple partners) prior to incarceration and 6 and 12 months after study enrollment using data obtained as part of a randomized controlled trial...
May 2016: Nursing Research
Leandro N da Silva, Divânia D da Silva França, Nativa H A Del-Rio, Megmar A Dos Santos Carneiro, Regina M B Martins, Rafael A Guimarães, Raquel S Pinheiro, Ana L N Junqueira, Karlla A A Caetano, Sheila A Teles
Crack cocaine users represent a target group for hepatitis B vaccination. We evaluate the HBV epidemiology, immunization status and compliance with a super-accelerated vaccination schedule among in-treatment crack cocaine users in central Brazil. Six hundred in-treatment crack cocaine users were interviewed, and serum samples were tested for HBV markers. A super-accelerated vaccination schedule of HBV vaccine was offered to all susceptible crack cocaine users. In total, 7.0% of those tested had at least one positive marker of HBV exposure...
January 2017: Journal of Infection and Public Health
Heng Chi, Pauline Arends, Jurriën G P Reijnders, Ivana Carey, Ashley Brown, Massimo Fasano, David Mutimer, Katja Deterding, Ye H Oo, Jörg Petersen, Florian van Bommel, Robert J de Knegt, Teresa A Santantonio, Thomas Berg, Tania M Welzel, Heiner Wedemeyer, Maria Buti, Pierre Pradat, Fabien Zoulim, Bettina E Hansen, Harry L A Janssen
BACKGROUND AND AIM: The incidence and consequences of flares during first-line nucleos(t)ide analogue therapy are largely unknown. We aimed to investigate the incidence and outcome of alanine aminotransferase (ALT) flares during long-term entecavir (ETV) in chronic hepatitis B (CHB). METHODS: CHB patients treated with ETV monotherapy from 11 European centers were studied. Flare was defined as > 3× increase in ALT compared with baseline or lowest on-treatment level and an absolute ALT > 3× ULN...
November 2016: Journal of Gastroenterology and Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"